EP1237538A2 - An improved pharmaceutical composition for treating male erectile dysfunction - Google Patents
An improved pharmaceutical composition for treating male erectile dysfunctionInfo
- Publication number
- EP1237538A2 EP1237538A2 EP00990872A EP00990872A EP1237538A2 EP 1237538 A2 EP1237538 A2 EP 1237538A2 EP 00990872 A EP00990872 A EP 00990872A EP 00990872 A EP00990872 A EP 00990872A EP 1237538 A2 EP1237538 A2 EP 1237538A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- pharmaceutical composition
- sildenafil
- improved pharmaceutical
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Abstract
The invention disclosed in this application relates to a novel pharmaceutical composition containing sildenafil useful for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes. The composition is also effective in patients with erectile dysfunction due to spinal cord injury. The pharmaceutical composition of the present invention is in the form of a solution or a colloidal dispersion in a pharmaceutical vehicle filled into specially designed dosing device for nasal administration. The invention disclosed in this application also provides a method for preparing the pharmaceutical composition containing sildenafil for nasal application for the treatment of male erectile dysfunction.
Description
AN IMPROVED PHARMACEUTICAL COMPOSITION FOR TREATING MALE ERECTILE DYSFUNCTION.
The present invention relates to an improved pharmaceutical composition containing sildenafil intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes. The composition is also particularly effective in patients with erectile dysfunction due to spinal cord injury. The pharmaceutical composition of the present invention may be in the form of a solution or a colloidal dispersion in a pharmaceutical vehicle. The composition can be filled into specially designed dosing device for nasal administration.
Sildenafil has the chemical formula C22H30N O4S
Sildenafil is potent and selective inhibitor of type V cyclic guanosine mono phosphodiestrase (cGMP) with utility for the treatment of male erectile dysfunction. Recently, it has been hypothesized that penile erections are dependent on nitric oxide (NO) and its second messenger cGMP. Sildenafil amplifies the neuronal nitric oxide (NO) / cGMP pathway implicated in the relaxation of the corpus cavernosum. The drug is well tolerated orally. Headache, dyspepsia, facial flushing and muscular ache are the common adverse events reported [Steers, W. D. et al. 2nd Meet Eur. Soc. Impotence Res. (Oct 1- 4, Madrid) 1997, Abst 80]. It is administered orally at a dose of 25mg to lOOmg. Sildenafil treated patients have a significant improvement in sex life satisfaction rating compared with the placebo groups [Terret et al. Bio Org. Med.Chem. Lett., 6(15),1819-1824(1996); Boolell. et al. Br.J.Urol. 78(2),257-261(1996)].
The pharmaceutical compositions available in the markets for oral administration contains sildenafil citrate (M/s Pfizer Inc.). Sildenafil citrate is soluble in dimethylformamide, sparingly soluble in acetic acid, slightly soluble in alcohol. About 3.5 mg is soluble in water.
In JP 10298062 a pharmaceutical composition in the form of tablets that rapidly soluble in the oral cavity and manufacturing procedure has been disclosed.
In WO 9830209 a rapidly releasing and taste masking pharmaceutical composition comprising a core containing Sildenafil, an inner coating layer formed of a water soluble polymer and an outer coating layer formed on inner coating containing saliva insoluble polymer and a process for preparing such oral dosage form has been disclosed.
According to the above patents sildenafil is administered orally about one hour before intercourse. This is a major disadvantage of the oral formulations, creating in convenience to the partners. Rapid onset of action is highly desirable in such therapeutic indication for patients. Considering the above parameters an attempt has been made to develop an intranasal formulation containing sildenafil citrate or base in a solution form which possesses rapid onset of action at a reduced dose when compare to the oral dosage form available for the treatment of male erectile dysfunction.
With the development of various devices for application of drugs in the nasal cavity and the specialized anatomy and physiology of nasal cavity and its ready accessibility made the nasal cavity a particularly attractive delivery site for the systemic administration of drugs, since no injection is required, and first pass metabolism is circumvented.
Although the permeability of nasal epithelium to drug molecules varies greatly depending on the physicochemical properties of the drug, a number of strategies have been explored to increase the nasal membrane permeability. These include
1) increasing the residence time of the drug in the nasal mucosa.
2) increasing the blood flow to the nasal mucosa.
3) modifying drug-membrane characteristic with surface-active agents.
In US patent, US 5,874,437 ni rosated and nitrosylated phosphodiestrase inhibitors having the formula NOn , where n = 1 or 2 and compositions comprising such compound in pharmaceutically acceptable carrier and a method for treating male impotence in humans by administering the compounds and compositions thereof has been disclosed.
In WO 00/00199 an intranasal dosage unit of cyclic guanosine monophosphate specific phosphodiesterase inhibitors are described which are combined with suitable intranasal carriers having a buffer, surfactant and absorption enhancers, in order to achieve a peak plasma concentration of the inhibitor in less than 1 hour, and desirably with in 30 minutes of administration in mammals. In this active ingredient is dispersed in a buffer followed by thickening agent, humectant and surfactant are added.
However the disadvantage associated with this type of suspension formulations is that the dispersed drug particles in the viscous medium may have to over come the resistance caused by the medium to reach onto the surface of the mucous membrane for its dissolution and penetration through the membrane. Further the drug is in solid state with less fluid volume and surface area made available for dissolution and penetration that reduces the absorption of drug compared to solution. The dispersion system may delay onset of action initially,
though it prolongs the duration of action due to slow penetration. The delay m the onset of action may cause patient incompliance. Further, the limited solubility of the sildenafil citrate may leads to improper dosing of the formulation.
In EP 0967214 intranasal formulations of Sildenafil mesylate together with a pharmaceutically acceptable diluent or carrier for the treatment of male erectile dysfunction or female sexual disorders are described. In this, sildenafil free base is added to an aqueous solution of methane sulfonic acid and solubility enhancer (Caffeine) and a buffer are added. Similarly compositions are prepared using nicotinamide, vanillin or benzyl alcohol instead of caffeine as penetration enhancers.
However, the above process in making the solution involves the conversion of sildenafil into mesylate followed by solubilising the mesylate salt. This process involves conversion of sildenafil to mesylate salt, which is tedious and time consuming.
The above patent also claimed an intranasal powder formulation by using sildenafil mesylate and lactose. The composition was milled to an average particles of 20 microns size and filled into a gelatin capsule for use with a commercial nasal device. Inhalation of this powder may cause irritation to the mucous membrane, and absorption of the active ingredient is slow compared to the solution form as described above.
In WO 9966933 a method for rapidly and reliably delivering sildenafil to the systemic circulation of a patient intranasally in a pharmaceutical composition contained sildenafil or a pharmaceutically acceptable salts and carrier was disclosed. According to this method sildenafil citrate was dissolved with the help of mesylic acid and the pH adjusted to 2.8 to 3.0 with sodium hydroxide. It has also disclosed a "sildenafil nasal spray solution" containing sildenafil hydrochloride dissolved in phosphate buffer and isotonicity adjusted with sodium chloride.
It also discloses an "aqueous nasal gel" which contains sildenafil hydrochloride, methocel and an acetate buffer. It has also disclosed a composite nasal spray solution containing sildenafil hydrochloride, and apomorphine hydrochloride.
Considering the importance attached to removal of the drawbacks/disadvantages of the presently available composition containing sildenafil we undertook research work towards developing an improved composition which can be administered through nasal route wherein the active drug gets rapidly absorbed.
The main objective of the present invention is to provide an improved pharmaceutical composition intended for nasal administration for the treatment of male erectile dysfunction due to organic, pyschogenic and mixed causes containing sildenafil for nasal application.
Yet another objective of the present invention is to provide an improved pharmaceutical composition in the foπΗ of a solution or colloidal dispersion intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes containing sildenafil for nasal application in a suitable pharmaceutical vehicle, comprising of a solvent, co- solvent and / or solubilizing agent, penetration enhancer, stabilising agent, buffering agent, and a tonicity agent; optionally contain an anti-microbial agent and / or viscosity modifying agents.
Still another objective of the invention is to provide a method for preparing the improved pharmaceutical composition containing sildenafil in the form of a solution or colloidal dispersion intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes.
The present invention is based on our finding that the poorly water soluble sildenafil or its salt, dissolves completely in mild acids such as lactic acid, hydrochloric acid, ascorbic acid, citric acid, succinic acid, maleic acid, orthophosphoric acid or methyl sulfonic acid and the resulting solution when mixed with solubilisers and penetration enhancers such as polyethyleneglycol, propylene glycol, glycerol, ethyl alcohol, purified diethylene glycol monoethyl ether, propyleneglycol monolaurate and the pH is adjusted 3.0 to 8.0 with citrate, acetate or phosphate buffer and tonicity is adjusted with sodium chloride or dextrose or mannitol, the resulting composition acquires unique property of promoting rapid absorption of sildenafil resulting in rapid onset of action when administered through the nasal route due to synergistic activities of the above said components. It was noticed that the free base of sildenafil is preferably more soluble in ascorbic acid and diethylene glycol monoethyl ether.
We have further noted that lactic acid, is more preferable as it is highly biocompatible and is present in organs such as lever, kidney, thymus gland, stratum corneum, human amniotic fluid and other organs and body fluids.
The above said pharmaceutical composition has rapid onset of action upon administration through nasal route with out any adverse effects due to the synergistic effect of the ingredients employed in the composition which results in keeping the active ingredient namely sildenafil or its salt in solution or dispersion foπΗ and absorption is further promoted by penetration enhancers
making it absorb readily when the composition is administered through the nasal route for eliciting the desired therapeutic response.
The above said composition can be filled into a suitable container fitted with nasal applicator. The composition can be filled either in multiple dose container fitted with an applicator or "Monospray" (supplied by M/s Valois India Pvt., Ltd., 407, Madhava,Bandra-kurla Complex, Bondra(E), Mumbai- 400 051), filled with single dose of medicament.
Accordingly, the present invention provides an improved pharmaceutical composition intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes in the form of solution or colloidal dispersion, which comprises solution or colloidal dispersion of Sildenafil or its salt in a "Protogenic" solvent containing solubilisers and penetration enhancers, stabilizing agent, buffering agents and an isotonicity agent, the solution or the dispersion having a pH in the range of 3.0 to 8.0.
The solution or the dispersion is stable at room temperature and sub ambient temperatures as well without any precipitation and/or re-crystallisation. The composition is not a mere admixture of the ingredients employed resulting in a composition having the aggregate properties of the said ingredients. The composition in solution form is preferred to the dispersion form as the former has more rapid absorption and onset of action than that of a dispersion form.
The pharmaceutical composition so formed is then filled in either a multiple dose containers fitted with a mechanical pump and a nasal applicator with an over cap or a "Monospray" (supplied by M/s Valois India Pvt., Ltd., 407, Madhava, Bandra-kurla Complex, Bondra(E), Mumbai- 400 051), nasal liquid unidose device. The preferred device is "Monospray".
Sildenafil employed in the pharmaceutical composition may be the base or its salt form with organic acids such as citric acid, lactic acid, acetic acid, succinic acid, maleic acid and the like or inorganic acids such as sulphuric acid, hydrochloric acid, orthophosphoric acid etc.
The amount of sildenafil or its salt employed in the pharmaceutical composition may range from 2.5 to 25.0% w/v, preferably 5.0 to 20.0% w/v more preferably 7.5 to 15.0% w/v.
The pH of the pharmaceutical composition may preferably be in the range of 3.5 to 5.0.
The "Protogenic" solvents, which act as proton donors, used m the pharmaceutical composition may be selected from a group of mild acids such as hydrochloric acid, sulphuric acid, lactic acid, solutions of ascorbic acid, citric acid and amphiprotic solvents such as water or their mixtures. The volume of such solvents present in the pharmaceutical composition may range from 10.0 to 80.0%v/v, preferably 20.0 to 60.0% v/v.
The co-solvents when used in the pharmaceutical composition may be selected from a group of "Amphiprotic" solvents, which act as both proton acceptors and proton donors such as the alcohols e.g. ethyl alcohol, propylene glycol, glycerol and polyethylene glycols having a nominal molecular weight of 200 - 600 or N- methyl-2-pyrrolidone, which enhances the solubility of sildenafil or its salts by formation of complex. The volume of such co-solvents present in the pharmaceutical composition may range from 1.0 to 50.0% v/v preferably 15.0 to 30.0% v/v.
The solubilising agents used in the pharmaceutical composition may be selected from purified diethylene glycol monoethyl ether, cyclodextrins, glycerol monostearate, lecithin, poloxomer, polyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, stearic acid, citric acid, and ascorbic acid and the like; surface active agents such as polysorbates, sorbiton esters, polyvinyl alcohol, benzal konium chloride, benzithonium chloride, cetrimide, docusate sodium, sodium lauryl sulphate, octoxynol and the like or a combination of these. The amount of such solubilising agent present in the pharmaceutical composition may range from 0.01 to 30.0% w/v, preferably 5.0 to 15.0%w/v.
The solubility enhancers used in the composition may be selected from DL- methionine, caffeine, nicotinamide, vanillin, benzyl alcohol, known in art as solubility enhancers when added to the solutions of other substances.
The buffering agent used in the pharmaceutical composition may be selected from hydrochloric acid, sodium acetate, glacial acetic acid, orthophosphoric acid, potassium dihydrogen orthophosphate and the like.
The penetration enhancers used in the pharmaceutical composition of the present invention are selected from ethyl alcohol, propylene glycol, N-methyl-2- pyrrolidone, bile salts, cyclodextrins, propyleneglycol monolaurate in combination with purified diethylene glycol monoethyl ether and the like known in the art for intranasal application. The amount of such penetration enhancer present in each ml of the composition may range from 0.1 to 30.0%v/v or w/v, preferably 5.0 to 25.0%v/v or w/v.
The stabilizing agent used in the pharmaceutical composition maybe selecteα from among those substances known in the art such as sodium metabisulphite, sodium bisulphite, disodium EDTA, ascorbic acid etc. The amount of such stabilizing agents present in the composition may range from 0.01 to 0.5% w/v.
The pharmaceutical composition may optionally contain anti-microbial agent. The anti-microbial agent may be selected from benzyl alcohol, benzalkonium chloride, phenyl mercuric acetate, phenylethyl alcohol and the like. The amount of such anti-microbial agent may range from 0.001 to 2.0% w/v preferably 0.02 to 0.5%w/v
The pharmaceutical composition may also optionally contain a viscosity building agent to increase the viscosity of the composition, there by prolongs the contact time of the composition with the nasal mucosa, preventing its rapid drain to the larynx region of throat. The viscosity building agent may be selected from hydrocolloids such as hydroxypropyl methylcellulose, poly acrylic acid and the like or water soluble polymers such as carbopol, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and various grades of polyvinylpyrrolidone i.e. K-15, K-30, K-60 and K-90 etc. The amount of such viscosity building agent used in the pharmaceutical composition may range from 0.1 to 5.0% /v.
The "Monospray" is a nasal liquid unidose device useful in administrating high potency molecules enabling less frequent administration and treatment of crisis conditions. The device comprises an actuator with over cap, spring, piston, dosage chamber and a ball for closing the dosage chamber from rear end after filling with medicine. A "Monospray" with a nominal volume of the dosage chamber in between 50.0 to 150.0 microliters is selected to deliver 2.5 to 37.5mg, preferably 5.0 to 25.0mg, more preferably 7.5 to 15.0 mg of active substance.
When a multiple dose container is used the percentage of the drug dissolved may range from 2.5 to 25.0%w/v preferably from 5.0 to 15.0%w/v more preferably from 7.5 to 15.0% w/v. The dose required may constitute one or more number of actuations depending on the dosing device used and the concentration of drug present in the formulation.
The invention is described in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
EXAMPLE - 1
Each ml contains
Sildenafil citrate 7.500 % w/v
Lactic acid 10.000 % v/v
Sodium acetate 0.041 % w/v
Glacial acetic acid 0.057 % v/v
Phenylethyl alcohol 0.500 % v/v
Pyrogen free water to make up to 1.0 ml
Sildenafil citrate is dissolved in lactic acid and pyrogen free water. Phenylethyl alcohol is added as preservative. Sodium acetate and Glacial acetic acid are added to adjust the pH 3.0. Final volume adjusted to 1.0ml with pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
EXAMPLE - 2
Each ml contains
Sildenafil citrate 7.500 % w/v
N-methyl-2-pyrrolidone 10.000 % v/v
Potassium dihydrogen Orthophosphate 1.360 % w/v
Orthophospharic acid 0.080 % v/v
Benzalkonium chloride 0.020 % v/v
Pyrogen free water to make up to 1.0 ml
Sildenafil citrate is dissolved in mixture of N-methyl-2-pyrrolidone, and pyrogen fee water Benzalkonium chloride solution is added, pH is adjusted to 3.5 with Potassium dihydrogen orthophosphate and Phosphoric acid. Final volume is adjusted to 1.0ml with Pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray" .
EXAMPLE - 3
Each ml contains
Sildenafil citrate 10.000 % w/v
Polyethylene glycol - 300 30.000 % v/v
Ethyl alcohol 20.000 % v/v
Hydrochloric acid 10.000 % v/v
Pyrogen free water to make up to 1.0 ml
Sildenafil citrate is dissolved in a mixture of polyethylene glycol. ethyl alcohol and hydrochloric acid. pH is adjusted to 3.0 with sodium hydroxide. Pyrogen free water is added to make up to one ml. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray" .
EXAMPLE - 4
Each ml contains Sildenafil citrate 7.500 % w/v
Propylene glycol 20.000 % v/v
Ethyl alcohol 20.000 % v/v
Hydrochloric acid 10.000 % v/v
Pyrogen free water to make up to 1.0ml
Sildenafil citrate is dissolved in a mixture of propylene glycol, ethyl alcohol and hydrochloric acid. pH is adjusted 3.0 with sodium hydroxide. Pyrogen free water is added to make up the volume to one ml. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
EXAMPLE - 5
Each ml contains Sildenafil citrate 10.000 % w/v Polyethylene glycol - 300 30.000 % v/v
Glycerol 20.000 % v/v
Hydrochloric acid 10.000 % v/v
Pyrogen free water to make up to 1.0ml
Sildenafil citrate is dissolved in a mixture of polyethylene glycol, glycerol, hydrochloric acid. pH is adjusted to 3.2 with sodium hydroxide. Pyrogen free water is added to make up to one ml. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
EXAMPLE - 6
Each ml contains Sildenafil citrate 10.000 % w/v
Purified diethylene glycol monoethyl ether 2.000 % w/v
Octoxynol 0.007 % w/v
Sodium ascorbate 5.000 % w/v
Disodium EDTA 0.020% w/v
Polyvinylpyrrolidone (K-30) 1.000% w/v
Phenyl ethyl alcohol 0.500 % v/v
Pyrogen free water to make up to 1.0ml
Sildenafil citrate is dissolved in a mixture of pyrogen free water, purified diethylene glycol monoethyl ether and octoxynol. Disodium EDTA, polyvinylpyrrolidone K-30, Sodium ascorbate and phenyl ethyl alcohol are added to the above solution. pH is adjusted to 4.0 with sodium acetate and glacial acetic acid. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
EXAMPLE - 7
Each ml contains
Sildenafil free base 7.500 % w/v
Ascorbic acid 5.000 % w/v
Disodium EDTA 0.020% w/v
Polyvinylpyrrolidone (K- 15) 2.000% w/v
Purified diethylene glycol monoethyl ether 1.000 % w/v
Benzyl alcohol 0.200 % v/v
Pyrogen free water to make up to 1.0ml
Sildenafil is dissolved in a mixture of pyrogen free water, purified diethylene glycol monoethyl ether. Ascorbic acid, disodium EDTA, Polyvinylpyrrolidone, benzyl alcohol are added under continuous mixing. pH is adjusted to 4.0 with sodium acetate and glacial acetic acid. Final volume adjusted to one ml with pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
EXAMPLE - 8
Each ml contains Sildenafil citrate 10.000 % w/v
Hydrochloric acid 10.000% w/v
Sodium acetate 0.180% w/v
Glacial acetic acid 3.100% w/v
Disodium EDTA 0.020% w/v
Purified diethylene glycol monoethyl ether 0.500 % w/v
Polyvinylpyrrolidone (K-l 5) 2.000% w/v
Propylene glycol 2.000% w/v
Phenyl ethyl alcohol 0.500% w/v
Pyrogen free water to make up to 1.0ml
Sildenafil citrate is dissolved in a mixture of pyrogen free water and hydrochloric acid. Purified diethylene glycol monoethyle ether, disodium EDTA, polyvinylpyrrolidone (K-l 5), propylene glycol and phenyl ethyl alcohol is added under continuous mixing. pH is adjusted to 4.0 with sodium acetate and glacial acetic acid. Final volume is adjusted to one ml with pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
Advantages:
Advantages of the invention are
1) Rapid onset of action when compared to conventional oral formulation of sildenafil.
2) Reduction in the total amount of drug required to elicit desire therapeutic response there by reducing the side effects.
3) Improved patient compliance
4) Accurate dosing compared to other extravascular routes.
Claims
We Claim:
01)An improved pharmaceutical composition, intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes in the form of solution or colloidal dispersion, which comprises a synergistic solution or colloidal dispersion of sildenafil or its salt in a "Protogenic" solvent containing solubisers penetration enhancers, stabilizing agent, buffering agents and an isotonicity agent, the solution or the dispersion having a pH in the range of 3.0 to 8.0, the composition incorporated in a conventional container fitted with a mechanical pump and a nasal applicator.
02)An improved pharmaceutical composition as claimed in claim 1 where in the salt form of sildenafil employed is selected form the salt formed by reacting sildenafil with ascorbic acid, citric acid, lactic acid, acetic acid, methyl sulphonic acid, succinic acid, maleic acid, sulfuric acid, hydrochloric acid, nitric acid, orthophosphoric acid, preferably ascorbic acid, methyl sulphonic acid and hydrochloric acid and the amount used ranges from 2.5 to 25.0% w/v, preferably form 5.0 to 20.0% w/v more preferably from 7.5 to 15.0% w/v.
03)An improved pharmaceutical composition as claimed in claims 1 and 2 where in the solvent used is selected from water, diluted hydrochloric acid, diluted sulphuric acid, lactic acid and the like are employed in the nasal solution and the amount ranges from 10.0 to 80.0% v/v, preferably 20.0 to 60.0% v/v.
04)An improved pharmaceutical composition as claimed in claims 1 to 3 where in the co-solvent(s) such as ethyl alcohol, propylene glycol polyethylene glycols having a nominal molecular weight of 200 to 600, N-methyl-2- pyrolidone, glycerol or a mixture thereof are employed and the amount used ranges from 1.0 to 50.0% v/v, preferably from 15.0 to 30.0% v/v.
05)An improved pharmaceutical composition as claimed in claims 1 to 4where in the solubilizing agents such as purified diethylene glycol monoethyl ether, cyclodextrins, glycerol monostearate, lecithin, poloxomer, polyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, stearic acid, citric acid, and ascorbic acid and the like; surface active agents such as polysorbates, sorbiton esters, polyvinyl alcohol, benzal konium chloride, benzithonium chloride, cetrimide, docusate sodium, sodium lauryl sulphate, octoxynol and the like or a combination of these are employed.
06)An improved pharmaceutical composition as claimed in claims 1 to 5 here in the solubility enhancers such as benzyl alcohol, DL-Methionine, nicotinamide, vanillin, caffeine are employed and the amount used ranges from 1.0 to 20.0% w/v preferably 5.0 to 15.0% w/v.
07)An improved pharmaceutical composition as claimed in claims 1 to 6 where in (i)buffering agents such as diluted hydrochloric acid, sodium hydroxide, sodium acetate, glacial acetic acid, disodium hydrogen orthophosphate, potassium dihydrogen orthophosphate, orthophosporic acid and the like (ii) penetration enhancer such as ethyl alcohol, propylene glycol, N-methyl-2- pyrrolidone, bile salts, cyclodextrins, and a mixture of propyleneglycol monolaurate and purified diethylene glycol monoethyl ether and the like (iii) stabilizing agent such as sodium metabisulphite, sodium bisulphite, disodium ethylene diamine terra acetic acid, ascorbic acid and the like (iv) antimicrobial preservatives such as benzyl alcohol, benzalkonium chloride, phenyl mercuric acetate, phenylethyl alcohol and the like (v) viscosity building agent such as hydrocollids such as hydroxypropyl methyl cellulose, poly acrylic acid and the like or water soluble polymers such as carbopol, sodium carboxy methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, various grades of polyvinylpyrrolidone i.e. K-l 5, K-30, K-60 and K-90 are employed.
08)A process for the preparation of improved pharmaceutical composition as claimed in claims 1 to 7 which comprises dissolving or dispersing sildenafil or its salt in a "Protogenic" solvent containing solubilizers and penetration enhancers, stabilizing agent, buffering agent, tonicity agent and adjusting the pH of the resulting solution or dispersion in the range of 3.0 8.0 the composition filled in a conventional container fitted with mechanical pump and nasal applicator.
09)An improved pharmaceutical composition intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic, and mixed causes in the form of solution or colloidal dispersion substantially as herein described with reference to the Examples 1 to 8.
10) A process for the preparation of an improved pharmaceutical composition intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes in the form of solution in colloidal dispersion substantially as herein described with reference to the Examples 1 to 8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1128MA1999 | 1999-11-18 | ||
| INMA112899 | 1999-11-18 | ||
| PCT/IN2000/000105 WO2001035926A2 (en) | 1999-11-18 | 2000-10-24 | An improved pharmaceutical composition for treating male erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1237538A2 true EP1237538A2 (en) | 2002-09-11 |
Family
ID=11096782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00990872A Withdrawn EP1237538A2 (en) | 1999-11-18 | 2000-10-24 | An improved pharmaceutical composition for treating male erectile dysfunction |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1237538A2 (en) |
| AU (1) | AU3048501A (en) |
| CA (1) | CA2391968A1 (en) |
| WO (1) | WO2001035926A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
| US20100184722A1 (en) | 2008-12-19 | 2010-07-22 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
| BR112012031297B1 (en) * | 2010-06-07 | 2020-03-03 | Suda Ltd. | FORMULATION OF ORAL SPRAY BIO AVAILABLE AND USE OF THE SILDENAFIL BASE |
| RU2611403C1 (en) * | 2011-12-05 | 2017-02-21 | Суда Лимитед | Compositions in the form of a spray for oral administration and methods of the sildenafil administration |
| GB2497933B (en) * | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| ES2475942B1 (en) * | 2013-01-11 | 2015-04-16 | Farmalider, S.A. | Pharmaceutical composition of sildenafil citrate in the form of an aqueous solution |
| FR3008618A1 (en) * | 2013-07-19 | 2015-01-23 | Univ Paris Curie | USE OF COMPOUNDS TO RESTORE THE RESPONSE IN THE LIGHT OF CELLS OF THE RETINA |
| NO2723977T3 (en) * | 2014-03-19 | 2018-03-10 | ||
| WO2016161397A1 (en) * | 2015-04-03 | 2016-10-06 | Insys Development Company, Inc. | Sildenafil sublingual spray formulations |
| EP3331888A4 (en) * | 2015-08-03 | 2019-03-20 | Synergistic Therapeutics, LLC | Sexual dysfunction therapeutic gel |
| WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| CN114028348B (en) * | 2021-10-09 | 2022-11-08 | 南京长澳医药科技有限公司 | Sildenafil citrate orally disintegrating tablet and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1309561A (en) * | 1997-05-29 | 2001-08-22 | 持田制药株式会社 | Therapeutic agent for erection failure |
| TWI223598B (en) * | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6200591B1 (en) * | 1998-06-25 | 2001-03-13 | Anwar A. Hussain | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction |
| DE19834506A1 (en) * | 1998-07-31 | 2000-02-03 | Hexal Ag | Transmucosal therapeutic system for the use of sildenafil |
-
2000
- 2000-10-24 WO PCT/IN2000/000105 patent/WO2001035926A2/en not_active Application Discontinuation
- 2000-10-24 CA CA002391968A patent/CA2391968A1/en not_active Abandoned
- 2000-10-24 EP EP00990872A patent/EP1237538A2/en not_active Withdrawn
- 2000-10-24 AU AU30485/01A patent/AU3048501A/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0135926A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001035926A2 (en) | 2001-05-25 |
| CA2391968A1 (en) | 2001-05-25 |
| WO2001035926A3 (en) | 2001-12-27 |
| AU3048501A (en) | 2001-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6200591B1 (en) | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction | |
| KR100810872B1 (en) | Compositions for treatment of common cold | |
| US20040171666A1 (en) | Therapeutic compositions for intranasal administration which include KETOROLAC | |
| JP2003501468A (en) | Nasal delivery of apomorphine | |
| PT1112075E (en) | Compositions for the treatment of male erectile dysfunction | |
| EP1782816B1 (en) | Water-based medicinal composition containing azithromycin and method of preparing the same | |
| JP2004091490A (en) | cGMP-PDE INHIBITOR FOR TREATING ERECTION DYSFUNCTION | |
| EP1250925B1 (en) | Nasal spray containing ondansetron hydrochloride | |
| KR20020016832A (en) | Compositions and methods comprising morphine gluconate | |
| EP1237538A2 (en) | An improved pharmaceutical composition for treating male erectile dysfunction | |
| JP2003515559A (en) | Pharmaceutical preparations containing zolmitriptan | |
| US20090246273A1 (en) | Ketorolac Sublingual Spray for the Treatment of Pain | |
| KR20030087072A (en) | Compositions Containing Imidazotriazinone For Nasal Application | |
| US20020002175A1 (en) | Nasal delivery of apomorphine in combination with glycol derivatives | |
| JPH03287535A (en) | Aqueous solution of pranoprofen | |
| US20080003275A1 (en) | Treatment of Premature Ejaculation | |
| JP2011524366A (en) | Pharmaceutical formulation of ketorolac for intranasal administration | |
| JP2729859B2 (en) | Reversible thermogelling aqueous pharmaceutical composition | |
| WO2000000193A1 (en) | Methods and pharmaceutical formulations for preventing and treating motion sickness | |
| US20210379080A1 (en) | Intranasal Formulation | |
| JPH07215877A (en) | Nasal drop | |
| EP1136072A1 (en) | Preparations for intraurethral administration | |
| BG62197B1 (en) | Antimigraine preparation with internasal administration | |
| JP2002037735A (en) | Method for stabilizing caffeines and composition to be applied to mucous membrane | |
| US7645765B2 (en) | Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020617 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17Q | First examination report despatched |
Effective date: 20031110 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20051122 |